Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled 16-Week Study (With a 52-Week Open-Label Extension) to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis
Conditions
Interventions
Etrasimod 1 mg
Etrasimod 2 mg
+1 more
Locations
38
United States
Noble Clinical Research
Tucson, Arizona, United States
Hope Clinical Research
Canoga Park, California, United States
First OC Dermatology
Fountain Valley, California, United States
Marvel Research LLC
Huntington Beach, California, United States
ADVA Clinical Research, Inc
Inglewood, California, United States
Providence Clinical Research
North Hollywood, California, United States
Start Date
October 4, 2019
Primary Completion Date
September 9, 2020
Completion Date
October 11, 2021
Last Updated
November 4, 2022
NCT07217015
NCT07298395
NCT06116526
NCT06461897
NCT07262983
NCT06389136
Lead Sponsor
Arena Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions